The disappearing surplus makes it unlikely that Congress will pass any significant tax cuts, especially tax cuts for businesses, before 2002. Surprisingly, the tax bill passed early in 2001 and "hyped" as being primarily for individual taxpayers, offers relief for many urologists and their practices.
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.